文献速递胸部肿瘤

SMYD3通过RNF113A甲基化-磷酸化交叉调控阻碍小细胞肺癌对烷化损伤的敏感性

SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk.
PubMed 文献 · Cancer Discov · 2022-01-01

该研究鉴定赖氨酸甲基转移酶SMYD3是小细胞肺癌(SCLC)对烷化剂化疗敏感性的主要调控因子。SMYD3介导的RNF113A甲基化损害其与磷酸酶PP4的相互作用,调控RNF113A磷酸化水平;这种翻译后修饰交叉对话是维持RNF113A E3连接酶活性的关键开关。抑制SMYD3可恢复SCLC对烷化剂化疗的脆弱性,为小分子SMYD3抑制剂改善化疗应答提供依据。

要点

  • SMYD3是SCLC对烷化剂化疗敏感性的主要调控因子。
  • SMYD3介导的RNF113A甲基化通过影响PP4结合调控其磷酸化水平。
  • 抑制SMYD3可恢复SCLC对烷化剂化疗的敏感性。

核心结论

  • SMYD3通过RNF113A甲基化-磷酸化交叉对话调控SCLC对烷化损伤的敏感性,抑制SMYD3可恢复SCLC对烷化剂化疗的脆弱性。

研究设计与样本

  • 原文未报告研究设计与样本。

主要发现

  • SMYD3介导的RNF113A甲基化损害其与磷酸酶PP4的相互作用,控制RNF113A磷酸化水平。
  • RNF113A翻译后修饰交叉对话是促进和维持其E3连接酶活性的关键开关,对其在烷化损伤应答中的作用至关重要。
  • 抑制SMYD3可恢复SCLC对烷化剂化疗的脆弱性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Small cell lung cancer (SCLC) is the most fatal form of lung cancer, with dismal survival, limited therapeutic options, and rapid development of chemoresistance. We identified the lysine methyltransferase SMYD3 as a major regulator of SCLC sensitivity to alkylation-based chemotherapy. RNF113A methylation by SMYD3 impairs its interaction with the phosphatase PP4, controlling its phosphorylation levels. This cross-talk between posttranslational modifications acts as a key switch in promoting and maintaining RNF113A E3 ligase activity, essential for its role in alkylation damage response. In turn, SMYD3 inhibition restores SCLC vulnerability to alkylating chemotherapy. Our study sheds light on a novel role of SMYD3 in cancer, uncovering this enzyme as a mediator of alkylation damage sensitivity and providing a rationale for small-molecule SMYD3 inhibition to improve responses to established chemotherapy. SIGNIFICANCE: SCLC rapidly becomes resistant to conventional chemotherapy, leaving patients with no alternative treatment options. Our data demonstrate that SMYD3 upregulation and RNF113A methylation in SCLC are key mechanisms that control the alkylation damage response. Notably, SMYD3 inhibition sensitizes cells to alkylating agents and promotes sustained SCLC response to chemotherapy. This article is highlighted in the In This Issue feature, p. 2007.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Lukinović V, Hausmann S, Roth GS, et al. SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. Cancer Discov. 2022. PMID: 35819319. doi:10.1158/2159-8290.CD-21-0205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。